- BriaCell Therapeutics (BCTX) priced a public offering of 5.37M units, with each unit consisting of one common share and one warrant.
- Each unit is being sold to the public at a price of $5.59 per unit for gross proceeds of ~$30M.
- The offering is expected to close on January 15, 2026.
- The company intends to use the net proceeds to fund working capital requirements, general corporate purposes and the advancement of the company’s business objectives.
- The stock price dropped 9.7% on Tuesday during after-market hours of trading.
BrianCell Therapeutics drops 10%, prices $30M offering at $5.59 per unit (BCTX:NASDAQ)
